Pipeline

Elcelyx Therapeutic's lead product, NewMet for Type 2 diabetes is a proprietary delayed-release formulation of metformin. NewMet represents a reduced-risk, near-term blockbuster opportunity in diabetes, with longer-term opportunities in obesity and pre-diabetes.